Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ERN1 | O75460 | 3/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449698 | 0.85 | CES2 (0.45) | ALDH1A1CES2CES1MEN1KMT2A | |
| SCHEMBL30870831 | 0.82 | CES2 (0.67) | F10SMN1; SMN2CES2CES1MEN1 | |
| SCHEMBL2540656 | 0.82 | CES2 (0.67) | F10SMN1; SMN2CES2CES1MEN1 | |
| SCHEMBL5095020 | 0.82 | HPGD (0.59) | F10ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL289656 | 0.82 | KMT2A (0.57) | ALDH1A1SMN1; SMN2CES2CES1MEN1 | |
| SCHEMBL15386976 | 0.81 | F10 (0.49) | F10ALDH1A1HPGDSMN1; SMN2F2 | |
| SCHEMBL2540654 | 0.81 | F10 (0.49) | F10ALDH1A1HPGDSMN1; SMN2F2 | |
| SCHEMBL7950682 | 0.79 | AKR1C3 (0.66) | F10ALDH1A1HPGDSMN1; SMN2F2 | |
| SCHEMBL15386970 | 0.79 | LMNA (0.56) | F10ALDH1A1HPGDSMN1; SMN2F2 | |
| SCHEMBL7406706 | 0.79 | MEN1 (0.55) | F10ALDH1A1HPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-11433071-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-09-06 | — | — | US | disclosed |
| EP-3888657-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3513793-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| EP-2134179-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090203687-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7452993-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| EP-1778687-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | STRUCTURAL GENOMIX, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| WO-2006015124-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | F10 4009/4885ALDH1A1 3232/4885HPGD 678/4885 |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | F10 4009/4885ALDH1A1 3232/4885HPGD 678/4885 |
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | MAP3K20, TTK, MAP3K19 | F10 3718/4885ALDH1A1 4383/4885HPGD 2710/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | F10 4009/4885ALDH1A1 3232/4885HPGD 678/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | F10 4009/4885ALDH1A1 3232/4885HPGD 678/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | F10 803/4885ALDH1A1 444/4885HPGD 211/4885 |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | F10 3718/4885ALDH1A1 4383/4885HPGD 2710/4885 |
| US-11433071-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | F10 4009/4885ALDH1A1 3232/4885HPGD 678/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | F10 4009/4885ALDH1A1 3232/4885HPGD 678/4885 |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | F10 4009/4885ALDH1A1 3232/4885HPGD 678/4885 |
| US-20090203687-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | F10 3718/4885ALDH1A1 4383/4885HPGD 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.